<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660010</url>
  </required_header>
  <id_info>
    <org_study_id>M90-516</org_study_id>
    <nct_id>NCT00660010</nct_id>
  </id_info>
  <brief_title>Study of Lupron Depot In The Treatment of Central Precocious Puberty</brief_title>
  <official_title>Study of Lupron Depot In The Treatment of Central Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and
      effective in treating children with Central Precocious Puberty (CPP), and to assess long term
      effects of leuprolide acetate treatment after therapy is discontinued.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes a Prestudy Period; a treatment period where subjects will receive
      treatment every 4 weeks until the initiation of puberty (age 12 for males and age 11 for
      females); a follow-up period where subjects will be observed every 6 months until physical
      and laboratory observations are at pubertal levels, then every 12 months for 5 years; lastly
      a final follow-up questionnaire is given to all subjects when they are at least 18 years old.

      At the treatment visits, efficacy assessments are Tanner staging (suppression of breast
      development in females and genital development in males), gonadotropins (LH and FSH), sex
      steroids (estradiol in females and testosterone in males), ratio of bone age to chronological
      age, adult height compared to a standard population and predicted mature height, and age and
      time to regular menses in females. This protocol will also capture data from the final
      questionnaire about female reproductive status at adulthood including the presence of regular
      menses and number of pregnancies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1991</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)</measure>
    <time_frame>Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)</measure>
    <time_frame>Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations</measure>
    <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Stimulated Estradiol Concentrations in Females</measure>
    <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Stimulated Testosterone Concentrations in Males</measure>
    <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Ratio of Bone Age to Chronological Age</measure>
    <time_frame>Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
    <description>Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Puberty, Precocious</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lupron (leuprolide acetate)</intervention_name>
    <description>Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of isosexual central precocious puberty with onset of Tanner scores
             of Stage II for breast or pubic hair earlier than age 8.0 years in girls or Stage II
             for pubic hair or genitalia earlier than 9.0 years in boys.

          -  Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone
             (GnRH) stimulation test (LH &gt; 10 U/L at baseline).

          -  Chronological age less than 9.0 years in girls or less than 10.0 years in boys at time
             of first dosing.

          -  Bone age advanced at least 1 year beyond the chronological age at entry into the
             study.

          -  The condition may be idiopathic or secondary to another lesion. If secondary, therapy
             of the primary condition will have been undertaken and stabilized.

          -  No evidence of abnormal pituitary, adrenal, thyroid and gonadal function except for
             premature secretion of gonadotropins.

        Exclusion Criteria:

          -  Irradiation to the central nervous system.

          -  Prior therapy with medroxyprogesterone acetate and/or with any GnRH analog (including
             prior treatment with daily subcutaneous and depot formulations of leuprolide acetate).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristof Chwalisz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46673</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46671</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14921</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14343</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14341</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14342</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46672</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46668</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14344</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <results_first_submitted>April 22, 2010</results_first_submitted>
  <results_first_submitted_qc>June 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2010</results_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kristof Chwalisz, MD, PhD Therapeutic Area Head</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>CPP</keyword>
  <keyword>central precocious puberty</keyword>
  <keyword>pediatrics</keyword>
  <keyword>suppression of LH</keyword>
  <keyword>Lupron</keyword>
  <keyword>leuprolide acetate</keyword>
  <keyword>depot formulation</keyword>
  <keyword>GnRHa</keyword>
  <keyword>GnRH agonist</keyword>
  <keyword>GNRH analog</keyword>
  <keyword>LH</keyword>
  <keyword>Tanner staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study included 1 treatment group and subjects were assigned the initial dosage depending on their weight. The minimum starting dose was 7.5 mg every 28 days. Study drug was discontinued either when puberty occurred at 12 years +- 6 months for males and 11 years +- 6 months for females or at the discretion of the investigator.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Leuprolide Acetate 1 Month Depot</title>
          <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with visit schedule</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leuprolide Acetate 1 Month Depot</title>
          <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)</title>
        <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).</description>
        <time_frame>Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 49 females (breast development suppression). Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)</title>
          <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).</description>
          <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 49 females (breast development suppression). Study drug was discontinued at the initiation of puberty.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Breast development suppression - Week 4 N=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression-Week 48 N=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9" lower_limit="66.7" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression -Week 96 N=41</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" lower_limit="73.8" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression-Week 144 N=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" lower_limit="64.2" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression - Week 192 N=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression -Week 240 N=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="46.2" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast development suppression-Final Visit N=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations</title>
        <description>Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.</description>
        <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 49 females and 6 males. Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations</title>
          <description>Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.</description>
          <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 49 females and 6 males. Study drug was discontinued at the initiation of puberty.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak stimulated LH at Baseline N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 4 N = 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 12 N = 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 24 N = 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 48 N = 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 96 N = 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 144 N = 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 192 N = 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Week 240 N = 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated LH at Final Visit N = 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Baseline N=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 4 N = 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 12 N = 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 24 N = 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 48 N = 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 96 N = 46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 144 N = 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 192 N = 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Week 240 N = 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak stimulated FSH at Final Visit N = 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Stimulated Estradiol Concentrations in Females</title>
        <description>Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.</description>
        <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>All females in the intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Stimulated Estradiol Concentrations in Females</title>
          <description>Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.</description>
          <population>All females in the intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean stimulated estradiol at baseline N=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="18.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 4 N=48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 12 N=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 24 N=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 48 N=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 96 N=39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 144 N=31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 192 N=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Week 240 N=13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated estradiol at Final Visit N=49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Stimulated Testosterone Concentrations in Males</title>
        <description>Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.</description>
        <time_frame>Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>All males in the intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Stimulated Testosterone Concentrations in Males</title>
          <description>Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.</description>
          <population>All males in the intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean stimulated testosterone at baseline N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.7" spread="121.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 4 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 12 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 24 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 48 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 96 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="19.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 144 N=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 192 N=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Week 240 N=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" spread="24.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean stimulated testosterone at Final Visit N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="17.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Ratio of Bone Age to Chronological Age</title>
        <description>Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.</description>
        <time_frame>Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ratio of Bone Age to Chronological Age</title>
          <description>Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.</description>
          <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. Study drug was discontinued at the initiation of puberty.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ratio at Baseline N=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 24 N=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 48 N=51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 96 N=44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 144 N=31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 192 N=26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Week 240 N=16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio at Final Visit N=53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)</title>
        <description>Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity &lt;1 cm/year or a bone age &gt;14 yrs in females or &gt;15 yrs in males.</description>
        <time_frame>Final ht. (measured or provided for final questionnaire in subjects &gt;= 18 years of age) or near final adult ht. (&lt;1 cm/year or bone age &gt; 14 years for females or &gt; 15 years for males)</time_frame>
        <population>For the follow-up posttreatment period, the ITT population=40 subjects and the safety population=55 subjects who received at least 1 injection of study drug during the treatment period. Study drug was discontinued at the initiation of puberty. The mean age of subjects at final questionnaire completion was 24.76 years with a range of 18.87 to 26.66.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)</title>
          <description>Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity &lt;1 cm/year or a bone age &gt;14 yrs in females or &gt;15 yrs in males.</description>
          <population>For the follow-up posttreatment period, the ITT population=40 subjects and the safety population=55 subjects who received at least 1 injection of study drug during the treatment period. Study drug was discontinued at the initiation of puberty. The mean age of subjects at final questionnaire completion was 24.76 years with a range of 18.87 to 26.66.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Near final adult ht. standardized score N=33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Near final ht.gain from predicted ht. at BL N=29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final adult ht.standardized score N=19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final adult ht.gain from predicted ht. at BL N=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Time to or Mean Age at Regular Menses in Females After Treatment</title>
        <description>Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.</description>
        <time_frame>Posttreatment during the follow-up period (subjects observed every 6 months until physical and laboratory observations are at pubertal levels)</time_frame>
        <population>During the posttreatment period, data were obtained from 32 female subjects. Twenty-seven subjects reported the start of menses, but only 26 subjects reported a menses start date.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to or Mean Age at Regular Menses in Females After Treatment</title>
          <description>Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.</description>
          <population>During the posttreatment period, data were obtained from 32 female subjects. Twenty-seven subjects reported the start of menses, but only 26 subjects reported a menses start date.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time to regular menses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at regular menses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Female Subjects Who Reported Regular Menses at Adulthood</title>
        <description>Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.</description>
        <time_frame>Posttreatment data were collected from the final adult questionnaire (subjects &gt;= 18 years of age)</time_frame>
        <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Female Subjects Who Reported Regular Menses at Adulthood</title>
          <description>Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.</description>
          <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of subjects with regular menses as adults</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of subjects without regular menses as adults</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects Who Reported Pregnancies at Final Questionnaire</title>
        <description>The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.</description>
        <time_frame>Posttreatment data were collected from the final adult questionnaire (subjects &gt;= 18 years of age)</time_frame>
        <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Pregnancies at Final Questionnaire</title>
          <description>The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.</description>
          <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects who reported being pregnant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects who were currently pregnant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Pregnancies Reported by Subjects at Final Questionnaire</title>
        <description>The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.</description>
        <time_frame>Posttreatment data were collected from the final adult questionnaire (subjects &gt;= 18 years of age)</time_frame>
        <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pregnancies Reported by Subjects at Final Questionnaire</title>
          <description>The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.</description>
          <population>A long-term follow-up questionnaire was sent to all subjects who completed at least 1 visit in the posttreatment follow-up period or who discontinued treatment because they entered puberty naturally at the appropriate age. Twenty female subjects (mean age 24.76 years, range 18.87 to 26.66 years) and 0 male subjects completed the questionnaire.</population>
          <units>Pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of pregnancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of live births</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of miscarriages</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)</title>
        <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).</description>
        <time_frame>Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit</time_frame>
        <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 6 males (genital development suppression). Study drug was discontinued at the initiation of puberty.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 1 Month Depot</title>
            <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)</title>
          <description>Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).</description>
          <population>The intent-to-treat (ITT) population and safety analysis set were identical for the treatment period. The starting population comprised 6 males (genital development suppression). Study drug was discontinued at the initiation of puberty.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Genital development suppression - Week 4 N=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Week 48 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Week 96 N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Week 144 N=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Week 192 N=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Week 240 N=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genital development suppression - Final Visit N=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each investigator monitored each subject for clinical and laboratory evidence of adverse events at Weeks 4, 8, 12, 24, 36, 48, and then every 6 months until the study drug was discontinued.</time_frame>
      <desc>Adverse events were reported from onset after the first injection of study drug through 30 days after treatment was completed. Treatment completion was defined as 28 days after the final study drug injection. The posttreatment follow-up period did not require the reporting of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Leuprolide Acetate 1 Month Depot</title>
          <description>Leuprolide acetate dosing was initiated at 300 mcg/kg (minimum dose 7.5 mg) administered intramuscularly (IM) every 28 days. Incremental adjustments to dosing at 3.75 mg increments were made at each visit.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart arrest</sub_title>
                <description>COSTART body system is cardiovascular system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Aggravation reaction</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Disorder</sub_title>
                <description>COSTART body system is musculoskeletal system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <description>COSTART body system is musculoskeletal system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Personality disorder</sub_title>
                <description>COSTART body system is nervous system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Repair of ventriculoperitoneal shunt</sub_title>
                <description>COSTART body system was not classified since it was a surgical repair.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <description>COSTART body system is hemic and lymphatic system</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <description>COSTART body system is special senses</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorder</sub_title>
                <description>COSTART body system is special senses</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>COSTART body system is digestive system</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>COSTART body system is digestive system</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>COSTART body system is digestive system</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>COSTART body system is digestive system</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Reaction unevaluable</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>COSTART body system is metabolic and nutritional disorders</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>COSTART body system is special senses</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>COSTART body system is urogenital system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vaginitis</sub_title>
                <description>COSTART body system is urogenital system</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental injury</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>COSTART body system is metabolic and nutritional disorders</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>COSTART body system is metabolic and nutritional disorders</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <description>COSTART body system is digestive system</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Growth retarded</sub_title>
                <description>COSTART body system is metabolic and nutritional disorders</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>COSTART body system is musculoskeletal system</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>COSTART body system is musculoskeletal system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <description>COSTART body system is musculoskeletal system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>COSTART body system is nervous system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>COSTART body system is nervous system</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Emotional Lability</sub_title>
                <description>COSTART body system is nervous system</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <description>COSTART body system is nervous system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Leukorrhea</sub_title>
                <description>COSTART body system is urogenital system</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <description>COSTART body system is urogenital system</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough increased</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>COSTART body system is respiratory system</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body odor</sub_title>
                <description>COSTART body system is body as a whole</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>COSTART body system is skin and appendages</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <description>COSTART body system is cardiovascular system</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study drug was discontinued usually at the initiation of puberty (12 years for males and 11 years for females) with the concurrence of the investigator, or at the discretion of the investigator. Adverse events are coded with the COSTART dictionary.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott Laboratories</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

